These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30703739)

  • 1. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
    Yonemori K; Shimomura A; Yasojima H; Masuda N; Aogi K; Takahashi M; Naito Y; Shimizu S; Nakamura R; Hashimoto J; Yamamoto H; Hirakawa A; Michimae H; Hamada A; Yoshida T; Sukigara T; Tamura K; Fujiwara Y
    Eur J Cancer; 2019 Mar; 109():84-91. PubMed ID: 30703739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    Kawachi A; Yamashita S; Okochi-Takada E; Hirakawa A; Tsuda H; Shimomura A; Kojima Y; Yonemori K; Fujiwara Y; Kinoshita T; Ushijima T; Tamura K
    Breast Cancer Res Treat; 2020 Jun; 181(2):323-329. PubMed ID: 32314111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
    Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
    Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
    Chen L; Yan X; Luo T; Tian T; He P; Zhong X
    Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.
    Yardley DA; Peacock N; Daniel B; Anz B; Molthrop DC; Shroff SK; Young R; Jankov A; Vander Woude A; Shastry M; Pasek J; DeBusk LM; Hainsworth JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):647-655. PubMed ID: 32060783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
    Bischoff J; Barinoff J; Mundhenke C; Bauerschlag DO; Costa SD; Herr D; Lübbe K; Marmé F; Maass N; von Minckwitz G; Grischke EM; Müller V; Schmidt M; Gerber B; Kümmel S; Schumacher C; Krabisch P; Seiler S; Thill M; Nekljudova V; Loibl S
    Anticancer Drugs; 2019 Apr; 30(4):394-401. PubMed ID: 30875348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Robson ME; Tung N; Conte P; Im SA; Senkus E; Xu B; Masuda N; Delaloge S; Li W; Armstrong A; Wu W; Goessl C; Runswick S; Domchek SM
    Ann Oncol; 2019 Apr; 30(4):558-566. PubMed ID: 30689707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
    Maeda S; Saimura M; Minami S; Kurashita K; Nishimura R; Kai Y; Yano H; Mashino K; Mitsuyama S; Shimokawa M; Tamura K;
    Breast; 2017 Apr; 32():66-72. PubMed ID: 28056400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer.
    Iwasa T; Tsurutani J; Watanabe S; Kato R; Mizuno Y; Kojima Y; Takashima T; Matsunami N; Morimoto T; Yamamura J; Ohtani S; Tanabe Y; Yoshinami T; Takano T; Komoike Y; Nakagawa K
    BMC Cancer; 2019 Oct; 19(1):962. PubMed ID: 31619197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
    Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M
    Br J Cancer; 2019 Feb; 120(3):279-285. PubMed ID: 30655615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
    Zhang P; Sun T; Zhang Q; Yuan Z; Jiang Z; Wang XJ; Cui S; Teng Y; Hu XC; Yang J; Pan H; Tong Z; Li H; Yao Q; Wang Y; Yin Y; Sun P; Zheng H; Cheng J; Lu J; Zhang B; Geng C; Liu J; Peng R; Yan M; Zhang S; Huang J; Tang L; Qiu R; Xu B;
    Lancet Oncol; 2017 Mar; 18(3):371-383. PubMed ID: 28209298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
    Marmé F; Gomez-Roca C; Graudenz K; Huang F; Lettieri J; Peña C; Trnkova ZJ; Eucker J
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):727-737. PubMed ID: 29468456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
    Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
    Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.